These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 21797104

  • 1. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
    Trenova AG, Manova MG, Kostadinova II, Murdjeva MA, Hristova DR, Vasileva TV, Zahariev ZI.
    Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
    [Abstract] [Full Text] [Related]

  • 2. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG, Slavov GS, Manova MG, Kostadinova II.
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [Abstract] [Full Text] [Related]

  • 3. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG, Slavov GS, Manova MG, Draganaova-Filipova MN, Mateva NG, Miteva LD, Stanilova SA.
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [Abstract] [Full Text] [Related]

  • 4. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients.
    Nguyen LT, Ramanathan M, Weinstock-Guttman B, Baier M, Brownscheidle C, Jacobs LD.
    J Neurol Sci; 2003 May 15; 209(1-2):93-9. PubMed ID: 12686409
    [Abstract] [Full Text] [Related]

  • 5. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D, Kataranovski M, Dincić E, Obradović S, Colić M.
    Vojnosanit Pregl; 2012 Feb 15; 69(2):151-6. PubMed ID: 22500369
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
    D'Angelo C, Reale M, Costantini E, Di Nicola M, Porfilio I, de Andrés C, Fernández-Paredes L, Sánchez-Ramón S, Pasquali L.
    Front Immunol; 2018 Feb 15; 9():1240. PubMed ID: 29915590
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
    Balasa R, Maier S, Voidazan S, Hutanu A, Bajko Z, Motataianu A.
    CNS Neurol Disord Drug Targets; 2015 Feb 15; 14(6):804-10. PubMed ID: 25801840
    [Abstract] [Full Text] [Related]

  • 10. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P, Romano MR, Boccardi B, Lombardo F, Moscato G, Mosti S, Baldini C, Nuti S, Meucci G, Rossi B.
    Rev Neurol; 2015 Feb 15; 29(10):893-9. PubMed ID: 10637835
    [Abstract] [Full Text] [Related]

  • 11. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H, Feng-Jun M, Osoegawa M, Minohara M, Murai H, Taniwaki T, Kira J.
    J Neurol Sci; 2004 Jul 15; 222(1-2):65-73. PubMed ID: 15240198
    [Abstract] [Full Text] [Related]

  • 12. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
    Trenova AG, Slavov GS, Draganova-Filipova MN, Mateva NG, Manova MG, Miteva LD, Stanilova SA.
    Neurol Res; 2018 Mar 15; 40(3):153-159. PubMed ID: 29297273
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Predictive value of early serum cytokine changes on long-term interferon beta-1a efficacy in multiple sclerosis.
    Petek-Balcı B, Çoban A, Shugaiv E, Türkoğlu R, Ulusoy C, İçöz S, Pehlivan M, Tüzün E, Akman-Demir G, Kürtüncü M, Eraksoy M.
    Int J Neurosci; 2015 May 15; 125(5):352-6. PubMed ID: 25026220
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
    Khademi M, Wallström E, Andersson M, Piehl F, Di Marco R, Olsson T.
    J Neuroimmunol; 2000 Mar 01; 103(2):202-10. PubMed ID: 10696916
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
    Minagar A, Ma W, Zhang X, Wang X, Zhang K, Alexander JS, Gonzalez-Toledo E, Albitar M.
    Neurol Res; 2012 Jul 01; 34(6):611-8. PubMed ID: 22709658
    [Abstract] [Full Text] [Related]

  • 19. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
    Sega S, Wraber B, Mesec A, Horvat A, Ihan A.
    Clin Neurol Neurosurg; 2004 Jun 01; 106(3):255-8. PubMed ID: 15177779
    [Abstract] [Full Text] [Related]

  • 20. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
    Kracke A, von Wussow P, Al-Masri AN, Dalley G, Windhagen A, Heidenreich F.
    Neurology; 2000 Jan 11; 54(1):193-9. PubMed ID: 10636147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.